title: Reduction of iatrogenic RPE lesions in AMD patients: evidence for wound healing?
abstract: OBJECTIVE
  Our purpose was to study retinal pigment epithelium (RPE) wound healing in patients with age-related macular degeneration (AMD).
  
  
  METHODS
  Abrasive debridement of nasal RPE was performed with a metal cannula during pars plana vitrectomy for foveal choroidal neovascularization (CNV) membrane excision combined with simultaneous autologous RPE transplantation. Fundus autofluorescence, fluorescein angiography images, and red-free pictures were taken initially within 1-2 weeks postoperatively, subsequently in 2-week intervals until 3 months, monthly until 6 months, and every 3 months thereafter. The borders of these lesions were measured; areas were calculated and compared using ArchiCad Software. Fourteen eyes of 14 patients suffering from AMD were included (nine women and four men, mean age 75.6 years +/-6.6 years).
  
  
  RESULTS
  Six of 14 (42.9 %) patients showed a reduction of the RPE debrided area. The size of these lesions reduced 5.6-20% within 2 postoperative months compared with their size at first examination (from a mean of 13.7 mm2 +/- 7.2 at baseline to a mean of 12.8 mm2 +/- 6.7 at 2 months postoperatively). No further reduction of the lesions was seen after the 2 months. In eight cases, borders of the RPE debrided areas stayed stable during observation time.
  
  
  CONCLUSIONS
  Wound healing of abrasively debrided RPE monolayer defects in patients with AMD occurs to a certain extent in nearly half of the cases. This process seems to stop after 2 months.
authors: The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Vienna, Austria. doris.rabenlehner@mediatrain.at
authors: Doris
authors: D
authors: Rabenlehner
authors: Boris V
authors: BV
authors: Stanzel
authors: Ilse
authors: I
authors: Krebs
authors: Susanne
authors: S
authors: Binder
authors: Alexandra
authors: A
authors: Goll
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D003646:Debridement; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control*; D008268:Macular Degeneration / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010857:Pigment Epithelium of Eye / Q000502:physiology* / Q000637:transplantation; D014821:Vitrectomy; D014945:Wound Healing
references: Arch Ophthalmol. 2004 Apr;122(4):598-614
references: 15078679
references: Eye (Lond). 1994;8 ( Pt 2):255-62
references: 7525361
references: Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3337-48
references: 15326159
references: Am J Ophthalmol. 2001 Apr;131(4):472-80
references: 11292411
references: Arch Ophthalmol. 1995 Jul;113(7):932-8
references: 7605287
references: Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3312-8
references: 12356840
references: Exp Eye Res. 2003 Apr;76(4):473-91
references: 12634112
references: Exp Eye Res. 1997 Jul;65(1):117-26
references: 9237872
references: Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4151-60
references: 15505069
references: Graefes Arch Clin Exp Ophthalmol. 2004 Jan;242(1):76-84
references: 14663593
references: Am J Ophthalmol. 2002 Feb;133(2):215-25
references: 11812425
references: Invest Ophthalmol Vis Sci. 1997 Feb;38(2):478-86
references: 9040481
references: Eye (Lond). 2001 Jun;15(Pt 3):384-9
references: 11450762
references: Curr Eye Res. 2003 Feb;26(2):81-8
references: 12815526
references: Physiol Rev. 2005 Jul;85(3):845-81
references: 15987797
references: Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4470-6
references: 15557456
references: Invest Ophthalmol Vis Sci. 1999 Feb;40(2):467-76
references: 9950607
references: Br J Ophthalmol. 1995 May;79(5):407-12
references: 7612549
references: Invest Ophthalmol Vis Sci. 1999 Feb;40(2):443-9
references: 9950604
references: Invest Ophthalmol Vis Sci. 1984 Oct;25(10):1135-45
references: 6480292
references: Graefes Arch Clin Exp Ophthalmol. 2004 May;242(5):442-3
references: 14740226
references: Br J Ophthalmol. 2004 Jan;88(1):110-3
references: 14693786
references: Invest Ophthalmol Vis Sci. 1995 Mar;36(3):718-29
references: 7890502
references: Invest Ophthalmol Vis Sci. 2003 May;44(5):2199-210
references: 12714662
references: Int Rev Cytol. 1997;171:225-66
references: 9066129
references: Trans Am Ophthalmol Soc. 2003;101:499-520
references: 14971591
references: Arch Ophthalmol. 1995 Jul;113(7):939-44
references: 7605288
references: Invest Ophthalmol Vis Sci. 1997 May;38(6):1094-109
references: 9152229
references: Graefes Arch Clin Exp Ophthalmol. 2002 Jan;240(1):12-6
references: 11954774
references: Am J Ophthalmol. 1996 Nov;122(5):629-43
references: 8909202
references: Br J Ophthalmol. 1996 Apr;80(4):314-8
references: 8703880
references: Ophthalmology. 1992 Jun;99(6):933-43
references: 1630784
references: Arch Ophthalmol. 1995 Nov;113(11):1437-46
references: 7487607
references: Exp Eye Res. 2005 Feb;80(2):235-48
references: 15670802
references: Birth Defects Orig Artic Ser. 1980;16(2):327-38
references: 7011436
references: Int Rev Cytol. 1994;150:119-37
references: 8169077
references: Arch Ophthalmol. 1984 Nov;102(11):1640-2
references: 6208888
references: Int Rev Cytol. 1994;152:223-63
references: 8206705
references: Br J Ophthalmol. 1997 Jun;81(6):481-9
references: 9274413
references: Exp Eye Res. 2005 May;80(5):595-606
references: 15862166
references: Invest Ophthalmol Vis Sci. 1997 Sep;38(10 ):2016-26
references: 9331265
references: Appl Opt. 1994 Nov 1;33(31):7439-52
references: 20941307
references: Am J Ophthalmol. 1996 Feb;121(2):181-9
references: 8623888
references: Invest Ophthalmol Vis Sci. 1988 Jul;29(7):1151-8
references: 3417404